The RECOVERY trial, a large randomised controlled trial in the UK to test five drugs, found that hydroxychloroquine drug did not cause significant reduction in mortality in hospitalised COVID-19 patients. Enrollment of participants to the hydroxychloroquine arm has been stopped with immediate effect.
The RECOVERY trial, a large randomised controlled trial in the UK to test five drugs, including hydroxychloroquine, has found no clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19. The trial investigators found that there was no significant benefit in mortality reduction in the intervention group, which was the primary objective.
The RECOVERY trial began in March. It is a dynamic trial assessing five candidate drugs and convalescent plasma therapy for treating COVID-19 in patients in UK hospitals. The trial has enrolled over 11,000 patients.
On 4 June, following the retraction of The Lancet paper on use of hydroxychloroquine, the UK Medicines and Healthcare Products Regulatory Agency wanted the independent Data Monitoring Committee of the RECOVERY trial to carry out an additional review. It also asked the investigators to look at the unblinded data in the hydroxychloroquine arm.
It then came to light that the drug did not have the desired beneficial effects. “We have concluded that there is no beneficial effect of hydroxychloroquine in patients hospitalised with COVID-19. We have therefore decided to stop enrolling participants to the hydroxychloroquine arm of the RECOVERY Trial with immediate effect,” a June 5 press release says.
What the numbers say
According to the release, a total of 1,542 patients were randomised to receive hydroxychloroquine for 10 days while 3,132 patients in the control arm received only standard care. The researchers found that there was “no significant difference in the primary endpoint of 28-day mortality”. While mortality was 25.7% in the intervention group, the control group had 23.5% mortality, which is not statistically significant.
There was no evidence of beneficial effects in hospital stay duration and other endpoints, either.
The primary outcome tested was reduction in all-cause mortality within 28 days of randomisation, and the secondary outcomes measured were to assess any reduction in duration of hospital stay and need for and duration of ventilator or ECMO within 28 days and up to six months after randomisation.
“These data convincingly rule out any meaningful mortality benefit of hydroxychloroquine in patients hospitalised with COVID-19,” the release says. The researchers will soon make the results available.
What does the result mean
“Hydroxychloroquine and chloroquine have received a lot of attention and have been used very widely to treat COVID patients despite the absence of any good evidence. The RECOVERY trial has shown that hydroxychloroquine is not an effective treatment in patients hospitalised with COVID-19,” Peter Horby, Professor of Emerging Infectious Diseases and Global Health in the Nuffield Department of Medicine, the University of Oxford, and Chief Investigator for the trial, says in the release.
Deputy Chief Investigator Martin Landray from the University of Oxford says: “There has been huge speculation and uncertainty about the role of hydroxychloroquine as a treatment for COVID-19, but an absence of reliable information from large randomised trials. The preliminary results from the RECOVERY trial are quite clear — hydroxychloroquine does not reduce the risk of death among hospitalised patients with this new disease.”
“The Recovery trial, in addition to the signals from other studies we have received so far, are enough to convince me to not offer hydroxychloroquine to hospitalized patients,” Nahid Bhadelia, a physician at Boston Medical Center, told Science. Porf. Landray added saying: “If you, your spouse, your mother gets admitted to hospital and is offered hydroxychloroquine, don’t take it,” he says.
Postexposure prophylaxis
Another trial found that hydroxychloroquine drug was not effective even as a postexposure prophylaxis in asymptomatic participants who have had high-risk exposure with a confirmed COVID-19 case. Nearly 88% (719 of 821 participants) had such high-risk exposure. The results of the trial published in The New England Journal of Medicine found that the incidence of COVID-19 illness was not statistically significantly in the group that received the drug compared with the control group. While 49 of 414 (11.8%) participants who received the drug developed illness, 58 of 407 (14.3%) participants who got the placebo fell ill. Side effects were more in the intervention group but no serious adverse events were reported.
Science Chronicle 